Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

Lipika Goyala Department of Medicine, Stanford University School of Medicine, & the Stanford Cancer Center, Palo Alto, CA, USA

Funda Meric-Bernstamb University of Texas MD Anderson Cancer Center, Houston, TX, USA

Antoine Hollebecquec Drug Development Department, Gustave Roussy, Villejuif, France

Juan W Valled Cholangiocarcinoma Foundation, Herriman, UT, USA;e Division of Cancer Sciences, University of Manchester, Manchester, UK

Chigusa Morizanef National Cancer Center Hospital, Tokyo, Japan

Thomas B Karasicg Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Thomas A Abramsh Mass General Cancer Center, Harvard Medical School, & Dana-Farber Cancer Institute, Boston, MA, USA

Junji Furusei Kanagawa Cancer Center, Yokohama, Japan

Robin Katie Kelleyj University of California, San Francisco, San Francisco, CA, USA

Philippe A Cassierk Centre Léon Bérard, Lyon, France

Heinz-Josef Klümpenl Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Heung-Moon Changm Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Li-Tzong Chenn National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Josep Taberneroo Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, University of Vic-Central University of Catalonia, Baselga Oncologic Institute, Hospital Quiron, Barcelona, Spain

Do-Youn Ohp Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

Amit Mahipalq Mayo Clinic, Rochester, MN, USA

Markus Moehlerr University Medical Center of Johannes Gutenberg University, Mainz, Germany

Yoshito Komatsus Hokkaido University Hospital Cancer Center, Sapporo, Japan

Daniel H Ahnt Mayo Clinic, Phoenix, AZ, USA

Robert S Epsteinu Epstein Health, Woodcliff Lake, NJ, USA

Abdel-Baset Halimv Taiho Oncology, Inc., Princeton, NJ, USA

Volker Wacheckv Taiho Oncology, Inc., Princeton, NJ, USA

Yaohua Hev Taiho Oncology, Inc., Princeton, NJ, USA

Mei Liuv Taiho Oncology, Inc., Princeton, NJ, USA

Karim A Benhadjiv Taiho Oncology, Inc., Princeton, NJ, USA

John A Bridgewaterw University College London Cancer Institute, London, UK

& for the FOENIX-CCA2 Study Investigators show all

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date